| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Diabetes and Metabolism Research Laboratories, Clinical Sciences Research Institute, Warwick Medical School; 2University Hospital of Coventry and Warwickshire, Coventry, England; and 3Heart Research Institute, Cardiff University, Wales, United Kingdom
Submitted 23 June 2006 ; accepted in final form 5 November 2006
Type 2 diabetes (T2DM) is associated with chronic low-grade inflammation. Adipose tissue (AT) may represent an important site of inflammation. 3T3-L1 studies have demonstrated that lipopolysaccharide (LPS) activates toll-like receptors (TLRs) to cause inflammation. For this study, we 1) examined activation of TLRs and adipocytokines by LPS in human abdominal subcutaneous (AbdSc) adipocytes, 2) examined blockade of NF-
B in human AbdSc adipocytes, 3) examined the innate immune pathway in AbdSc AT from lean, obese, and T2DM subjects, and 4) examined the association of circulating LPS in T2DM subjects. The findings showed that LPS increased TLR-2 protein expression twofold (P < 0.05). Treatment of AbdSc adipocytes with LPS caused a significant increase in TNF-
and IL-6 secretion (IL-6, Control: 2.7 ± 0.5 vs. LPS: 4.8 ± 0.3 ng/ml; P < 0.001; TNF-, Control: 1.0 ± 0.83 vs. LPS: 32.8 ± 6.23 pg/ml; P < 0.001). NF-B inhibitor reduced IL-6 in AbdSc adipocytes (Control: 2.7 ± 0.5 vs. NF-B inhibitor: 2.1 ± 0.4 ng/ml; P < 0.001). AbdSc AT protein expression for TLR-2, MyD88, TRAF6, and NF-B was increased in T2DM patients (P < 0.05), and TLR-2, TRAF-6, and NF-B were increased in LPS-treated adipocytes (P < 0.05). Circulating LPS was 76% higher in T2DM subjects compared with matched controls. LPS correlated with insulin in controls (r = 0.678, P < 0.0001). Rosiglitazone (RSG) significantly reduced both fasting serum insulin levels (reduced by 51%, P = 0.0395) and serum LPS (reduced by 35%, P = 0.0139) in a subgroup of previously untreated T2DM patients. In summary, our results suggest that T2DM is associated with increased endotoxemia, with AT able to initiate an innate immune response. Thus, increased adiposity may increase proinflammatory cytokines and therefore contribute to the pathogenic risk of T2DM.
toll-like receptors; adipocytes; nuclear factor-B; inflammation; insulin
This article has been cited by other articles:
|
|
 |
|
  A. Kiely, A. Robinson, N. H McClenaghan, P. R Flatt, and P. Newsholme Toll-like receptor agonist induced changes in clonal rat BRIN-BD11 {beta}-cell insulin secretion and signal transduction J. Endocrinol., September 1, 2009; 202(3): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shapiro, P. Singer, and J. Attal-Singer Comment on: Reyna et al. (2008) Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. Diabetes 57:2595-2602 Diabetes, April 1, 2009; 58(4): e5 - e5. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Reyna, S. Ghosh, R. A. DeFronzo, C. P. Jenkinson, and N. Musi Response to Comment on: Reyna et al. (2008) Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. Diabetes 57:2595-2602 Diabetes, April 1, 2009; 58(4): e6 - e7. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grunfeld and K. R. Feingold Endotoxin in the gut and chylomicrons: translocation or transportation? J. Lipid Res., January 1, 2009; 50(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Samokhvalov, P. J. Bilan, J. D. Schertzer, C. N. Antonescu, and A. Klip Palmitate- and lipopolysaccharide-activated macrophages evoke contrasting insulin responses in muscle cells Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E37 - E46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Dasu, S. Devaraj, L. Zhao, D. H. Hwang, and I. Jialal High Glucose Induces Toll-Like Receptor Expression in Human Monocytes: Mechanism of Activation Diabetes, November 1, 2008; 57(11): 3090 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ghanim, P. Mohanty, R. Deopurkar, C. Ling Sia, K. Korzeniewski, S. Abuaysheh, A. Chaudhuri, and P. Dandona Acute Modulation of Toll-Like Receptors by Insulin Diabetes Care, September 1, 2008; 31(9): 1827 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rodriguez-Calvo, L. Serrano, T. Coll, N. Moullan, R. M. Sanchez, M. Merlos, X. Palomer, J. C. Laguna, L. Michalik, W. Wahli, et al. Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-{kappa}B Activity via Extracellular Signal-Related Kinase 1/2 Diabetes, August 1, 2008; 57(8): 2149 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Babu, X. Meng, N. Zou, X. Yang, M. Wang, Y. Song, J. C. Cleveland, M. Weyant, A. Banerjee, and D. A. Fullerton Lipopolysaccharide Stimulation of Human Aortic Valve Interstitial Cells Activates Inflammation and Osteogenesis Ann. Thorac. Surg., July 1, 2008; 86(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J L Newton, D E J Jones, E Henderson, L Kane, K Wilton, A D Burt, and C P Day Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance Gut, June 1, 2008; 57(6): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. DiBaise, H. Zhang, M. D. Crowell, R. Krajmalnik-Brown, G. A. Decker, and B. E. Rittmann Gut Microbiota and Its Possible Relationship With Obesity Mayo Clin. Proc., April 1, 2008; 83(4): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Krogh-Madsen, P. Plomgaard, T. Akerstrom, K. Moller, O. Schmitz, and B. K. Pedersen Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E371 - E379. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
